For the quarter ended September 2025, Heron Therapeutics (HRTX) reported revenue of $38.21 million, up 16.5% over the same period last year. EPS came in at -$0.05, compared to -$0.03 in the year-ago quarter.
The reported revenue represents a surprise of -0.91% over the Zacks Consensus Estimate of $38.57 million. With the consensus EPS estimate being -$0.02, the EPS surprise was -150%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Heron Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Product Sales- Oncology- SUSTOL: $1.91 million versus $2.9 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -31.8% change.
- Net Product Sales- Acute Care- APONVIE: $3.03 million compared to the $2.99 million average estimate based on two analysts. The reported number represents a change of +175.8% year over year.
- Net Product Sales- Acute Care- ZYNRELEF: $9.31 million versus the two-analyst average estimate of $8.78 million. The reported number represents a year-over-year change of +47.8%.
- Net Product Sales- Oncology- CINVANTI: $23.96 million versus the two-analyst average estimate of $23.9 million. The reported number represents a year-over-year change of +6%.
View all Key Company Metrics for Heron Therapeutics here>>>
Shares of Heron Therapeutics have returned -11.9% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Heron Therapeutics, Inc. (HRTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
